Treatment with calcium antagonists has been shown to be beneficial in patients with primary and secondary Raynaud's phenomenon. A double-blind placebo-controlled crossover trial was performed to assess the efficacy of amlodipine, a new long-acting calcium antagonist, in patients with Raynaud's phenomenon without underlying disease. 20 of the 24 patients enrolled (20 women and 4 men, mean age 45 years) completed the trial. The number of episodes of Raynaud's phenomenon per week and the severity of discomfort significantly improved during amlodipine (p < 0.0001 and p < 0.0004, respectively) but not placebo treatment. Perfusion-pressure index, evaluated with Doppler sonography using a postischaemia reactive hyperaemia test, significantly improved (p < 0.04) after treatment with amlodipine but not placebo. These results indicate that amlodipine is a useful treatment for primary and suspected secondary Raynaud's phenomenon, at least in the short term.

Amlodipine in the treatment of Raynaud's phenomenon. A double blind placebo-controlled crossover study / La Civita, L.; Pitaro, N.; Rossi, M.; Giuggioli, D.; Gambini, I.; Cini, G.; Pasero, G.; Ferri, C.. - In: CLINICAL DRUG INVESTIGATION. - ISSN 1173-2563. - 13:1(1997), pp. 126-131. [10.2165/00044011-199700131-00022]

Amlodipine in the treatment of Raynaud's phenomenon. A double blind placebo-controlled crossover study

Giuggioli D.;
1997

Abstract

Treatment with calcium antagonists has been shown to be beneficial in patients with primary and secondary Raynaud's phenomenon. A double-blind placebo-controlled crossover trial was performed to assess the efficacy of amlodipine, a new long-acting calcium antagonist, in patients with Raynaud's phenomenon without underlying disease. 20 of the 24 patients enrolled (20 women and 4 men, mean age 45 years) completed the trial. The number of episodes of Raynaud's phenomenon per week and the severity of discomfort significantly improved during amlodipine (p < 0.0001 and p < 0.0004, respectively) but not placebo treatment. Perfusion-pressure index, evaluated with Doppler sonography using a postischaemia reactive hyperaemia test, significantly improved (p < 0.04) after treatment with amlodipine but not placebo. These results indicate that amlodipine is a useful treatment for primary and suspected secondary Raynaud's phenomenon, at least in the short term.
1997
13
1
126
131
Amlodipine in the treatment of Raynaud's phenomenon. A double blind placebo-controlled crossover study / La Civita, L.; Pitaro, N.; Rossi, M.; Giuggioli, D.; Gambini, I.; Cini, G.; Pasero, G.; Ferri, C.. - In: CLINICAL DRUG INVESTIGATION. - ISSN 1173-2563. - 13:1(1997), pp. 126-131. [10.2165/00044011-199700131-00022]
La Civita, L.; Pitaro, N.; Rossi, M.; Giuggioli, D.; Gambini, I.; Cini, G.; Pasero, G.; Ferri, C.
File in questo prodotto:
File Dimensione Formato  
lacivita1997.pdf

Accesso riservato

Descrizione: articolo prinicipale
Tipologia: Versione pubblicata dall'editore
Dimensione 608.31 kB
Formato Adobe PDF
608.31 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1226110
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 11
  • ???jsp.display-item.citation.isi??? 6
social impact